Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Neoadjuvant Treatment With Cyclooxygenase-2 Inhibitor and Prednisolone Allows Conservative Surgery for Inflammatory Myofibroblastic Tumor of the Bladder

Tsuma, Yusuke MD; Miyachi, Mitsuru MD, PhD; Ouchi, Kazutaka MD; Tsuchiya, Kunihiko MD, PhD; Iehara, Tomoko MD, PhD; Naitoh, Yasuyuki MD, PhD; Konishi, Eiichi MD, PhD; Yanagisawa, Akio MD, PhD; Hosoi, Hajime MD, PhD

Journal of Pediatric Hematology/Oncology: November 2016 - Volume 38 - Issue 8 - p e283–e285
doi: 10.1097/MPH.0000000000000604
Online Articles: Clinical and Laboratory Observations

Inflammatory myofibroblastic tumor (IMT), which expresses cyclooxygenase-2 (COX-2), can be effectively treated with COX-2 inhibitor. Here, we report a case of urinary bladder IMT in a 13-year-old boy. Although total cystectomy was initially planned for complete resection of the tumor, neoadjuvant treatment with COX-2 inhibitor and prednisolone reduced the size of the tumor and enabled complete resection of the tumor by partial cystectomy. Neoadjuvant treatment with COX-2 inhibitor and prednisolone for IMT of the bladder allowed a more conservative surgical procedure that preserved bladder function.

Departments of *Pediatrics

Urology, Graduate School of Medical Science

Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Supported by a JSPS KAKENHI Grant-in-Aid Number (A) 25253095. This manuscript discusses off-label use of loxoprofen and meloxicam.

The authors declare no conflict of interest.

Reprints: Mitsuru Miyachi, MD, PhD, Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan (e-mail:

Received August 25, 2015

Accepted May 16, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.